Breast cancer continues to be the second most common cause of cancer death in women in the United States. Results from numerous clinical trials continue to expand diagnostic/prognostic tools, therapeutic options, and supportive care strategies.
It is important for pharmacists to understand the long-term side effects of both systemic treatment and radiation in order to provide in-depth patient counseling, as well as appropriate therapy recommendations to the multidisciplinary team.
Several new options have recently been approved for the treatment of relapsed/refractory multiple myeloma. Pharmacists should be aware of the new data and recommendations surrounding these novel agents and how they relate to improvements in patient survival and quality of life.
In order to help patients make informed treatment decisions, health care professionals need to understand the clinical data regarding the indications and efficacy of novel therapies.
Click the Take Course button to access the evaluation.
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.
Click the Take Course button to access the evaluation.
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.
Click the Take Course button to access the evaluation.
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.
Clinicians must understand the treatment evolution and guidelines for administration of available therapies in the context of the patient's therapeutic and disease history to navigation through the complex treatment landscape.
Systemic therapy options in metastatic CRC are continuously evolving and new treatments are becoming available with utilization of various biomarkers. There is a need to review the current landscape of treatment regimens and have an understanding of their place in therapy.
Systemic therapy options in metastatic pancreatic cancer are evolving, including increasing usage of maintenance therapies. There is a need to review the current landscape of treatment regimens and have an understanding of their place in therapy.
Facebook
Twitter
LinkedIn
Forward
